#Hepatology Archives - Page 3 of 4

Gastroenterology丨Dr. Chuanlong Zhu: Analysis of a Rare Cause of Long-term Abnormal Liver Function in a Male Patient

By Mourabit Halima 2024.09.22

On August 27, 2024, the team led by Dr. Chuanlong Zhu from the Infectious Diseases Department at Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University) published a…

VITALITY Study Results Announced: Immunotherapy Shows Great Promise as a Neoadjuvant Treatment Before Liver Transplantation in Liver Cancer

By Lisa Cui 2024.09.19

Editor's Note: Immune checkpoint inhibitors (ICI) are gradually becoming a key therapeutic strategy in the neoadjuvant treatment of advanced hepatocellular carcinoma (HCC). Their widespread application reflects the deep understanding and…

Dr. Bo Feng: Classification and Differentiation of Hepatic Vascular Lesions

By Peter W. PENG 2024.09.13

Editor's Note: Hepatic vascular diseases include lesions in the hepatic artery, portal vein, hepatic vein, and hepatic sinusoids. Due to the lack of specific clinical manifestations, and differences in the…

Delicate and Thin Fibrous Septa Indicate a Regression Tendency in MASH Patients with Advanced Fibrosis

By Mourabit Halima 2024.09.11

Editor’s Note: Metabolic dysfunction-associated steatohepatitis (MASH) represents a severe subtype of metabolic dysfunction-associated fatty liver disease (MAFLD), a global public health issue affecting over 25% of the global population. MASH…

JOH | New Machine Learning Model Accurately Predicts Risk of Liver-Related Complications After Chronic Hepatitis B Cure

By Lisa Cui 2024.09.11

Recently, a research team led by Dr. Jeong-Hoon Lee from Seoul National University College of Medicine made significant strides in predicting the risk of liver-related outcomes (LROs) after functional cure…

PANoptosis-Related Gene Signature Predicts Prognosis and Immune Status in Biliary Tract Cancer Patients

By Peng Longmei 2024.09.11

Editor's Note: Biliary tract cancer (BTC) is the second most common primary liver malignancy after hepatocellular carcinoma (HCC), and its incidence has been rising globally over the past few decades.…

Gut丨HBcrAg Levels Can Predict Chronic Hepatitis B Patients’ Response to Interferon Therapy

By Mourabit Halima 2024.09.01

Editor's Note The current treatment options for chronic hepatitis B (CHB) primarily include long-term nucleos(t)ide analogs (NA) therapy and short-term interferon therapy. Although these approaches can control viral replication to…

Interventional Therapy in Hepatobiliary Diseases丨Dr. Xuefeng Luo: In-Depth Analysis of the French Guidelines on Transjugular Intrahepatic Portosystemi

By Mourabit Halima 2024.08.29

Editor's Note: Interventional therapy is an emerging clinical discipline that forms a crucial part of minimally invasive medicine, standing alongside traditional internal medicine and surgery as a key clinical specialty.…

Revisiting the “Gut-Liver-Brain Axis” through the Lens of Bile Acids – Key Advances and Prospects in Basic and Clinical Research

By Lisa Cui 2024.01.19

AASLD Roundtable Discussion: Revisiting the "Gut-Liver-Brain Axis" through the Lens of Bile Acids - Key Advances and Prospects in Basic and Clinical Research Editor's Note: The recently concluded AASLD 2023,…

AASLD Interview | Dr.Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development

By Mourabit Halima 2024.01.19

Editor's Note: At the just-concluded Annual Summit of Hepatology, the American Association for the Study of Liver Diseases (AASLD2023), Professor Fengmin Lu's team from Peking University presented three contributions (1…